{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-113593","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.514108+00:00","generated_at":"2026-06-08T23:29:33.945818+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cellectar to release top-line WM pivotal data at JP Morgan Conference week of Jan 8, 2024; raises up to $102.9M via PIPE","bullets":["Top-line data from Waldenstrom's macroglobulinemia pivotal trial to be released week of Jan 8, 2024 at JP Morgan Healthcare Conference.","Closed PIPE with up to $102.9M gross proceeds (milestone-based); initial $24.5M at $1.82/share; led by Rosalind Advisors.","Received EMA PRIME designation for iopofosine I 131 in WM after two or more prior treatments.","Cash of $19.0M at Sep 30; net $22.2M from PIPE; believes funded into Q2 2024.","Q3 R&D expense $7.3M (up from $5.4M YoY); G&A $2.1M (down from $2.4M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-113593","json":"https://secwatch.observer/filing/0001104659-23-113593.json","markdown":"https://secwatch.observer/filing/0001104659-23-113593.md","text":"https://secwatch.observer/filing/0001104659-23-113593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923113593/0001104659-23-113593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923113593/tm2329674d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:29:33.945818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4ed562d68bbbc035cf532ed0aa004acf7715b65","claim":"Cellectar Biosciences, Inc. reported preliminary financial results for three months ended September 30, 2023.","evidence_excerpt":"On November 2, 2023, we issued a press release announcing preliminary financial results for the three months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923113593/0001104659-23-113593-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}